Treatment of Suicidal Ideation in the Emergency Department Using Nitrous Oxide (PROTORISC)

This Phase II interventional trial (n=30), will investigate the efficacy of nitrous oxide in alleviating suicidal ideation (SI).

Suicide prevention is crucial, with thousands of suicides and attempts reported annually in France. While ketamine shows promise in reducing suicidal ideation, its side effects limit its use. Nitrous oxide, another NMDA receptor inhibitor, has demonstrated rapid antidepressant effects with minimal side effects. This trial aims to assess its potential in swiftly alleviating suicidal ideation.

Participants must have active suicidal ideation and be admitted to the psychiatric emergency department. They will receive either inhaled medical air or nitrous oxide for one hour.

The primary outcome measure is the decrease in suicidal ideation severity assessed at hour 4. Secondary measures include assessing depressive symptoms, anxiety intensity, and overall improvement at various time points.

The trial is conducted at University Hospital, Tours, France, and is estimated to start in June 2024 and complete in January 2026.

Topic Suicidality Depression
Compound Nitrous Oxide
Country France
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.